Anti-Angiogenesis Drug Discovery and Development

Anti-Angiogenesis Drug Discovery and Development

Volume: 4

The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of ...
[view complete introduction]

US $
30

*(Excluding Mailing and Handling)



Anti-Angiogenesis Drugs: Hopes and Disappointments in Certain Cancers

Pp. 97-107 (11)

Georgios M. Iatrakis

Abstract

In cancer, neovascularization seems necessary for tumor progression and metastasis. The hypothesis that cancer progression is angiogenesis-dependent has repeatedly been confirmed by experimental inhibition of tumor growth with angiogenesis inhibitors. Receptors for VEGF (VEGFRs) are expressed on tumor endothelium and tumor cells and, as expected, VEGF-A overexpression is associated with poor prognosis (reduced survival). There are both positive and negative angiogenesis regulators and, as such, two strategies for inhibiting pathologic angiogenesis can be adopted: the inhibition of positively-acting agents (e.g., VEGFR inhibitors) and the administration of negatively-acting agents (e.g., angiostatin (from the Greek words "angio" and "stasis" meaning stopping)).

Keywords:

Angiogenesis, Anti-angiogenesis drugs, Cancer, Growth factors, Negative angiogenesis regulators, Positive angiogenesis regulators.

Affiliation:

Technological Educational Institute of Athens, Αgiou Spyridonos, 12210 Egaleo, Athens, Greece.